

PRESS RELEASE
13/05/2025

Elena Erroba Assumes Representation of 3PBIOVIAN on the AseBio Board of Directors

Pamplona, May 27, 2025 – 3PBIOVIAN announces that **Elena Erroba**, the company's Chief Commercial Officer, will represent 3PBIOVIAN on the Board of Directors of **AseBio** (Spanish Bioindustry Association), replacing **Dámaso Molero**, the company's CEO.

Elena Erroba holds a Ph.D. in Biochemistry and an Executive MBA, with over 20 years of experience in the Biotechnology and Biomedicine sectors. She specializes in the development and manufacturing of recombinant proteins and advanced therapies, including viral vectors—such as adenoviruses and adeno-associated viruses—and DNA plasmids.

Over the past 15 years, Elena has led the commercial strategy at 3P Biopharmaceuticals (**now 3PBIOVIAN**), helping solidify its position as a key player in the development and production of biologic medicines. In addition to her executive role, Elena serves as an adjunct professor in the Science and Business program at the University of Navarra, where she shares her expertise at the intersection of science and business.

She began her professional career as a project manager at AseBio, giving her deep insight into the biotech ecosystem. This background, combined with her extensive experience at 3PBIOVIAN, makes her a **highly suitable figure to represent the company on AseBio's Board**, where she can make a valuable contribution to the development of the biotechnology sector in Spain.

"Taking on this responsibility is a challenge I embrace with great enthusiasm and commitment. AseBio has been instrumental in promoting and growing the biotechnology sector in Spain, and I am determined to continue supporting its initiatives to foster innovation and collaboration. I am deeply grateful for the trust 3PBIOVIAN has placed in me, and I will continue working to strengthen our position and contribute to the biotech ecosystem," said **Elena Erroba**, CCO of 3PBIOVIAN.

Dámaso Molero, CEO of 3PBIOVIAN, joined AseBio's Board of Directors in 2014 and has been a key figure in advancing biotechnology in Spain, where he continues to work tirelessly to strengthen the national biotech ecosystem. At 3PBIOVIAN, we are grateful for his outstanding work and the positive impact of his contributions to the association.

"It has been an honor to be part of AseBio's Board of Directors over the years, and I am pleased to know that Elena, with her expertise and knowledge of the sector, will continue representing 3PBIOVIAN with the same dedication and commitment. I am confident her contribution will be

PRESS RELEASE
13/05/2025

*of great value to AseBio and the biotech sector as a whole,” said **Dámaso Molero**, CEO of 3PBIOVIAN.*

3PBIOVIAN thus reaffirms its strong commitment to the progress AseBio drives in the biotech sector, actively supporting its initiatives to foster innovation, collaboration, and growth within the biotech ecosystem in Spain.

About 3PBIOVIAN

3PBIOVIAN is a global **Contract Development and Manufacturing Organization (CDMO)** providing comprehensive services to biotechnology and pharmaceutical companies. Its service portfolio includes expression and production platforms for proteins based on microbial strains and mammalian cells, plasmid DNA, and viral vectors for gene therapy (including adenoviruses and adeno-associated viruses), as well as cell therapy products. The company boasts state-of-the-art, technologically advanced facilities, including Fill and Finish services for recombinant proteins and viral vectors. 3PBIOVIAN operates two manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland, efficiently meeting the diverse needs of its clients—ranging from preclinical and clinical supply to large-scale commercial manufacturing.

www.3pbiovian.com

MEDIA CONTACTS

Spain

Edurne Gil
Head of Marketing and Communications
egil@3pbiovian.com
Phone: +34 948 34 64 80

Finland

Taru Värri
Marketing Manager
taru.varri@3pbiovian.com
Phone: +358 50 3650973